Google Translate Disclaimer

A number of pages on the Government of Saskatchewan`s web site have been professionally translated in French. These translations are identified by a yellow text box that resembles the link below and can be found in the right hand rail of the page. The home page for French-language content on this site can be found here:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

The results of software-based translation do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos, and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

Decisions Issued on Aurora Cannabis Inc., CanniMed Therapeutics Inc. Matter

Released on December 27, 2017

Financial and Consumer Affairs Authority of Saskatchewan (FCAA) issued decisions on December 22, 2017, with respect to the applications made regarding the Aurora Cannabis Inc. (Aurora) take-over bid of CanniMed Therapeutics Inc. (CanniMed).

The applications requested:
I. exemptive relief to shorten the minimum deposit period under the bid from 105 days to 35 days;
II. an order to cease trade the Shareholders Rights Plan of CanniMed;
III. that the companies that have entered into lockup agreements with Aurora, in respect of the bid, be treated as acting jointly and in concert with Aurora in making the bid; and
IV. a denial of Aurora’s ability under National Instrument 62-104 Take-over Bids and Issuer Bids to purchase additional securities of CanniMed, during the bid period.

The decisions were as follows:
I. trading will cease in any securities issued in connection with the Shareholders Rights Plan;
II. Aurora must amend, re-issue and file previous news releases by January 12, 2018, to include information that might affect shareholders decisions to accept or reject Aurora’s offer;
III. Aurora must amend the take-over bid circular to include the same information as included in the amended news releases by January 12, 2018;
IV. Aurora must distribute the Notice of Change to everyone the bid circular was required to be sent to, reflecting the changes to the take-over bid circular by January 12, 2018; and
V. other than some limited orders of confidentiality of parts of documents, all other requests were denied.

To review the Panel’s order visit

Reasons for the decisions will be posted to the hearing webpage above in due course.


For more information, contact:

Noel Busse
Phone: 306-787-8959

We need your feedback to improve Help us improve